Progyny (PGNY)
(Delayed Data from NSDQ)
$26.98 USD
-0.35 (-1.28%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $26.99 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PGNY 26.98 -0.35(-1.28%)
Will PGNY be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for PGNY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PGNY
Enhabit (EHAB) Beats Q1 Earnings Estimates
GeneDx Holdings Corp. (WGS) Reports Q1 Loss, Tops Revenue Estimates
PGNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Progyny (PGNY) is an Incredible Growth Stock: 3 Reasons Why
Earnings Preview: Charles River Laboratories (CRL) Q3 Earnings Expected to Decline
Earnings Preview: Progyny (PGNY) Q3 Earnings Expected to Decline
Other News for PGNY
Fertility Pioneer and Kindbody Founder Gina Bartasi Returns as CEO to Lead Company's Next Phase of Growth
Progyny: At This Price, Secular Tailwinds Are Too Compelling To Ignore
Progyny, Inc. to Present at Jefferies Global Healthcare Conference
Centene Corporation: A Great Business At A Great Price
Progyny: No Change To Long-Term Outlook